Our Services

Other Trials

Mutation Driven Trials

The trials listed below are for patients with a specific genomic alteration or rearrarangement. A genomic alteration or rearrangement is a change in the DNA within a gene, which can affect the way a cell works. Some genomic alterations are normal, but for patients with cancer, these alterations may be driving the cancer to grow. Sometimes, multiple alterations are causing a patient's cancer to grow. New treatments, called targeted therapies, target the genomic alterations that are causing the cancer to grow.

Novel TKI for Solid Tumors with NTRK1/2/3, ROS1, or ALK Gene Rearrangements Clinical Trial

  • Study name: STARTRK-2
  • Trial for patients with locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
  • Patients may have received prior treatment, but may also be treatment naïve
  • All patients will receive targeted therapy with Entrectinib, an oral TKI
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3814 or at Kimberly.Young@stjoe.org

ALK Inhibitor for Solid Tumors and Hematological Malignancies with ALK or ROS1 Gene Rearrangments Clinical Trial

  • Patients who have a confirmed diagnosis of a solid tumor (except ALK+ non-small cell lung cancer) or a hematological malignancy (blood cancer) and is in need of treatment
  • Patients with ROS1 rearranged non-small cell lung cancer may be included
  • All patients receive treatment with Ceritinib (LDK378), an oral ALK inhibitor
  • Patients must have received at least one prior treatment
  • Main study doctor (Principal Investigator): Thomas Stanton, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3814 or at Kimberly.Young@stjoe.org

Novel Multi-Kinase Inhibitor for Solid Tumors with RET Genetic Alteration Clinical Trial

  • Advanced solid tumors with a RET genetic alteration
  • Any line of therapy - can have received no prior treatment or various lines of therapy
  • All patients receive treatment with RXDX-105, a multi-kinase inhibitor
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3814 or at Kimberly.Young@stjoe.org

Other Non-Treatment Trials

FoundationOne Concordance Registry

  • Patients undergo one blood draw only
  • This trial is comparing the results of the blood draw (cfDNA) to the results of the tissue to see if FoundationOne finds the same mutations
  • All patients with a solid tumor who had their tissue submitted for FoundationOne testing and have a result within the past 2 years
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kayla Debenste, at 707-521-3829 or at Kayla.Denbeste@stjoe.org

Back to All Trials